FIELD: biotechnology.
SUBSTANCE: T-cell receptors (hereinafter – TCR) that bind with HLA-A*02-restricted SLLQHLIGL peptide (SEQ ID NO:1), a hybrid TCR/anti-CD3 molecule for the treatment of cancer, nucleic acid, an expression vector, a TCR expression cell, a T-cell not found in nature and/or purified and/or constructed for the adoptive cell therapy of cancer, a pharmaceutical composition for the treatment of cancer, a method for the treatment of a subject, a composition for injections for injecting to a subject, and a method for producing TCR or a hybrid TCR/anti-CD3 molecule are presented.
EFFECT: this group of inventions is used as new immunotherapeutic reagents for the treatment of a malignant disease.
37 cl, 9 dwg, 13 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| T-CELL RECEPTORS SPECIFIC RELATIVELY TO COMPLEX OF TUMOR ANTIGEN NY-ESO-1/HLA-A*02 | 2016 |
|
RU2775394C2 |
| T-CELL RECEPTORS | 2017 |
|
RU2775623C2 |
| HPV-SPECIFIC BINDING MOLECULES | 2018 |
|
RU2804664C2 |
| T-CELL RECEPTOR CONSTRUCTS AND THEIR USE | 2019 |
|
RU2785954C2 |
| POLYPEPTIDES RECRUITING T-CELLS, CAPABLE OF BINDING CD123 AND ALPHA/BETA TCR | 2017 |
|
RU2775063C2 |
| IMPROVED SYNTHETIC T-CELL RECEPTOR AND ANTIGEN RECEPTOR | 2021 |
|
RU2820497C1 |
| COMPOSITIONS AND LIBRARIES CONTAINING RECOMBINANT POLYNUCLEOTIDES ENCODING T-CELL RECEPTORS AND METHODS FOR USING RECOMBINANT T-CELL RECEPTORS | 2017 |
|
RU2752528C2 |
| ANTI-TRBC1 ANTIGEN-BINDING DOMAIN | 2018 |
|
RU2791327C2 |
| IMMUNOMODULATORY FUSED PROTEINS AND THEIR APPLICATION METHODS | 2016 |
|
RU2755227C2 |
| CHIMERIC ANTIGEN RECEPTOR (CAR) WITH ANTIGEN-BINDING DOMAINS TO THE T-CELL RECEPTOR β- CONSTANT REGION | 2015 |
|
RU2744046C2 |
